MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.

Merck held talks over a potential $3 billion acquisition of MoonLake Immunotherapeutics, as it seeks to replenish its drug pipeline ...

MoonLake’s stock rocketed 20% after reports claimed Merck made a $3 billion acquisition offer to boost its drug pipeline.

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times (FT) reported on Monday, citing three people familiar with the matter. MoonLake's ...

U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Tuesday. Shares of Signet Jewelers Limited ...

Merck submitted a nonbinding offer for the smaller biotech earlier in the year, according to a media report citing people ...

Biotech stock MoonLake Immunotherapeutics rocketed Tuesday on a report Merck offered to buy it for "more than $3 billion." ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a ...

Merck recently made a nonbinding offer to acquire Swiss biotech firm MoonLake for over $3 billion, seeking to boost its drug ...

Bill Ackman invested nearly half a billion dollars in the shares of collapsed federally backed agencies Fannie Mae and ...